Reflection Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Reflection Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$131K	Buy	+288	New	+$124K	0.09%	131

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Reflection Asset Management's VRTX Position: Q4 2025 in Review

Reflection Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2025: 288 shares worth $131K. The stake represents 0.09% of the portfolio and ranks #131 among its holdings.

1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Reflection Asset Management held 288 shares of Vertex Pharmaceuticals worth $131K as of Q4 2025.
Vertex Pharmaceuticals was a new Reflection Asset Management position in Q4 2025.
Vertex Pharmaceuticals made up 0.09% of Reflection Asset Management's portfolio in Q4 2025, its #131 holding.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Reflection Asset Management's 13F filing for Q4 2025, filed 2 Mar 2026.